1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Zeromectin 5 mg/ml Pour-on Solution for beef and dairy cattle, sheep and goats

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance:

Each ml contains:

Eprinomectin 5 mg.

Excipients:

Each ml contains:

Qualitative composition of excipients and other constituents	**Quantitative composition if that information is essential for proper administration of the veterinary medicinal product**
Butylated hydroxytoluene (E321)	10 mg
Propylene glycol dicaprylocaprate	

Clear Solution.

3. CLINICAL INFORMATION

3.1 Target species

Cattle (beef and dairy cattle), sheep, goats

3.2 Indications for use for each target species

Treatment of infestation by the following parasites:

Cattle:

Parasite	**Adult**	**L4**	**Inhibited L4**
Gastrointestinal Roundworms:			
Ostertagia spp.	◆	◆	
O. lyrata	◆		
O. ostertagi	◆	◆	◆
Cooperia spp.	◆	◆	◆
C. oncophora	◆	◆	
C. punctata	◆	◆	
C. surnabada	◆	◆	
C. pectinata	◆	◆	
Haemonchus placei	◆	◆	
Trichostrongylus spp.	◆	◆	
T. axei	◆	◆	
T. colubriformis	◆	◆	
Bunostomum phlebotomum	◆	◆	
Nematodirus helvetianus	◆	◆	
Oesophagostomum spp.	◆		
Oesophagostomum radiatum	◆	◆	
Trichuris spp.	◆		

Lungworm:		
Dictyocaulus viviparus	◆	◆

Warbles
(parasitic stages):
Hypoderma bovis
Hypoderma lineatum

Mange mites:
Chorioptes bovis
Sarcoptes scabiei var. *bovis*

Lice
Linognathus vituli
Damalinia bovis
Haematopinus eurysternus
Solenopotes capillatus

Flies:
Haematobia irritans

Prolonged activity: applied as recommended, the veterinary medicinal product prevents reinfestations with:

Parasite	Prolonged Activity
Dictyocaulus viviparus	Up to 28 days
Ostertagia ostertagi	Up to 28 days
Oesophagostomum radiatum	Up to 28 days
Cooperia punctata	Up to 28 days
Cooperia surnabada	Up to 28 days
Cooperia oncophora	Up to 28 days
Nematodirus helvetianus	Up to 14 days
Trichostrongylus colubriformis	Up to 21 days
Trichostrongylus axei	Up to 21 days
Haemonchus placei	Up to 21 days

Sheep

Gastrointestinal roundworms (adults)
Teladorsagia circumcincta (pinnata/trifurcata)
Haemonchus contortus
Trichostrongylus axei
Trichostrongylus colubriformis
Nematodirus battus
Cooperia curticei
Chabertia ovina
Oesophagostomum venulosum

Lungworm (adult)
Dictyocaulus filaria

Nasal Bots (L1, L2, L3)
Oestrus ovis

Goats
Gastrointestinal roundworms (adult)
Teladorsagia circumcincta (pinnata/trifurcata)
Haemonchus contortus
Trichostrongylus axei
Trichostrongylus colubriformis
Nematodirus battus
Cooperia curticei
Oesophagostomum venulosum

Lungworm (adult)
Dictyocaulus filaria

Nasal Bots (L1, L2, L3)
Oestrus ovis

Warbles (L1, L2, L3)
Przhevalskiana silenus

For best results the veterinary medicinal product should be part of a programme to control both internal and external parasites of cattle, sheep and goats based on the epidemiology of these parasites.

3.3 Contraindications

Do not use in other animal species. Avermectins can cause fatalities in dogs, especially Collies, Old English Sheepdogs and related breeds and crosses, and also in turtles/tortoises.
Do not use in cases of hypersensitivity to the active substance, or to any of the excipients.

3.4 Special warnings

For effective use, the veterinary medicinal product should not be applied to areas of the backline covered with mud or manure.

In cattle, rainfall before, during or after the application of the veterinary medicinal product, has been shown to have no impact on its efficacy. It also has been demonstrated that haircoat length has no impact on the veterinary medicinal product's efficacy. The effect of rainfall and haircoat length on efficacy has not been evaluated in sheep and goats.

In order to limit cross-transfer of eprinomectin, treated animals should preferably be separated from untreated animals. Non-compliance with this recommendation may lead to residue violations in untreated animals and development of resistance to eprinomectin.

Unnecessary use of antiparasitics or use deviating from the instructions given in the SPC may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the veterinary medicinal product should be based on confirmation of the parasitic species and burden, or of the risk of infestation based on its epidemiological features, for each herd/flock.

Repeated use for an extended period, particularly when using the same class of substances, increases the risk of resistance development. Within a herd/flock, maintenance of susceptible refugia is essential to reduce that risk. Systematically applied interval-based treatment and treatment of a whole herd/flock should be avoided. Instead, if feasible, only selected individual animals or subgroups should be treated (targeted selective treatment). This should be combined with appropriate husbandry and pasture management measures. Guidance for each specific herd/flock should be sought from the responsible veterinarian.

It is recommended to further investigate cases of suspected resistance, using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used. Confirmed resistance should be reported to the marketing authorisation holder or to the competent authorities.

To date no resistance to eprinomectin (a macrocyclic lactone) has been reported in cattle while resistance to eprinomectin has been reported in goats and sheep within the EU. However, resistance to other macrocyclic lactones has been reported in nematode populations in cattle, sheep and goats within the EU, which may be associated with side-resistance to eprinomectin. The use of this veterinary medicinal product should take into account local information about susceptibility of the target parasites, where available.
While mite and louse numbers decline rapidly following treatment, due to the feeding habits of some mites, in some cases several weeks may be required for complete eradication.

3.5 Special precautions for use

Special precautions for safe use in the target species:
For external use only.
The veterinary medicinal product should be applied only on healthy skin.

To avoid secondary reactions due to the death of *Hypoderma* larvae in the oesophagus or in the spine, it is recommended to administer the veterinary medicinal product at the end of warble fly activity and before the larvae reach their resting sites.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to the active substance or to any of the excipients should avoid contact with the veterinary medicinal product.
This veterinary medicinal product may be irritating to skin and eyes. Avoid contact with eyes and skin.

Personal protective equipment consisting of rubber gloves, boots and waterproof coat should be worn when handling the veterinary medicinal product.
Should clothing become contaminated, remove as soon as possible and launder before re-use.
If accidental skin contact occurs, wash the affected area immediately with soap and water. If accidental eye exposure occurs, flush eyes immediately with plenty of clean water. Should irritation persist, seek medical advice and show the package leaflet or the label to the physician.
Do not ingest.
In case of accidental ingestion, rinse out mouth thoroughly with water, seek medical advice immediately and show the package leaflet or the label to the physician.
Do not smoke, eat or drink while handling the veterinary medicinal product. Wash hands after use.

Special precautions for the protection of the environment:

Eprinomectin is very toxic to dung fauna and aquatic organisms, is persistent in soils and may accumulate in sediments.

The risk to aquatic ecosystems and dung fauna can be reduced by avoiding repeated use of eprinomectin (and products of the same anthelmintic class).
In order to reduce the risk to aquatic ecosystems, treated animals should not have direct access to water bodies for two to five weeks after treatment.

3.6 Adverse events

Cattle (beef and dairy cattle), sheep, goats:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Pruritus, Alopecia.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:
The veterinary medicinal product can be used in dairy cattle during pregnancy and lactation.
Laboratory studies (rat, rabbit) have not produced any evidence of a teratogenic or embryotoxic effects due to the use of eprinomectin at therapeutic doses.
Laboratory studies in cattle have not produced any evidence of a teratogenic or foetotoxic effect at the recommended therapeutic dose.

The safety of eprinomectin during pregnancy in sheep and goats has not been tested.
Use only according to the benefit-risk assessment by the responsible veterinarian.

3.8 Interaction with other medicinal products and other forms of interaction

None known.
Since eprinomectin binds strongly to plasma proteins, this should be taken into account if it is used in association with other molecules having the same characteristics.

3.9 Administration routes and dosage

Pour-on use.
For single application only.
To ensure a correct dosage, bodyweight should be determined as accurately as possible and accuracy of the dosing device should be checked. If animals are to be treated collectively, reasonably homogeneous groups should be set up, and all animals of a group should be dosed at the rate corresponding to the heaviest one.
Underdosing could result in ineffective use and may favour resistance development.

Dosage:

Cattle:
Administer by topical application at the dose rate of 0.5 mg/kg bodyweight of eprinomectin, corresponding to the recommended dose rate of 1 ml per 10 kg bodyweight.

Sheep and goats:
Administer by topical application at the dose rate of 1.0 mg/kg bodyweight of eprinomectin, corresponding to the recommended dose rate of 2 ml per 10 kg bodyweight.
When administering the veterinary medicinal product along the backline, part the fleece/coat and place applicator nozzle or bottle spout against the skin.

All the animals belonging to the same group should be treated at the same time.

Method of administration:
The product should be applied along the backline in a narrow strip extending from the withers to the tailhead.

For the 1 L presentation:
The bottle is equipped with an integrated dosing system and has two openings. One opening is connected to the body of the container and the other to the dispensing chamber (dosing system). Unscrew the tamper-evident cap and remove the seal of the dispensing chamber (integrated dosing system allowing 5 ml to 25 ml doses). Squeeze the bottle to fill the dispensing chamber with the required volume of product.

For the 2.5 L, 3 L and 5 L presentations:
To be used with an appropriate dosing system such as a dosing gun and coupling vented cap. Unscrew the polypropylene cap. Follow the gun manufacturer's instructions for adjusting the dose and proper use and maintenance of the dosing gun and vented cap. After use, coupling vented caps should be removed and replaced by the polypropylene cap.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No signs of toxicity appeared when 8-week-old calves were treated at up to 5x the therapeutic dose (2.5 mg Eprinomectin/kg b.w.) 3 times at 7-day intervals.
One calf treated once at 10x the therapeutic dose (5 mg/kg b.w.) in the tolerance study showed transient mydriasis. There were no other adverse reactions to treatment.

No signs of toxicity were observed when 17-week-old sheep were treated at doses up to 5 times the therapeutic dose (5 mg eprinomectin/kg bodyweight) 3 times at 14-day intervals.

No antidote has been identified.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Cattle:
Meat and Offal: 15 days.
Milk: Zero hours.

Sheep:
Meat and offal: 2 days.
Milk: zero hours.

Goats:
Meat and offal: 1 day.
Milk: zero hours.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QP54AA04.

4.2 Pharmacodynamics

Eprinomectin is a member of the macrocyclic lactone class of endectocides. Compounds of the class bind selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve or muscle cells. This leads to an increase in the permeability of the cell

membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite.
Compounds of this class may also interact with other ligand-gated chloride channels, such as those gated by the neurotransmitter gamma aminobutyric acid (GABA).
The margin of safety for compounds of this class is attributable to the fact that mammals do not have glutamate-gated chloride channels; the macrocyclic lactones have a low affinity for other mammalian ligand-gated chloride channels, and they do not readily cross the blood-brain barrier.

4.3 Pharmacokinetics

Eprinomectin is bound extensively to plasma proteins (99 %).

Pharmacokinetic studies have been conducted in lactating and non-lactating animals, administered topically at a single dosage of 0.5 mg/kg body weight in cattle and at 1 mg/kg bodyweight in sheep and goats.

For cattle, results from two representative studies found mean peak plasma concentrations of 9.7 and 43.8 ng/ml that were observed at 4.8 and 2.0 days post dose. The corresponding elimination half-lives in plasma were 5.2 and 2.0 days, and mean area-under-the-curve values of 124 and 241 ng*day/ml.
Eprinomectin is not extensively metabolized in cattle following topical administration. Faeces was the major route of elimination of the drug in beef cattle and dairy cows.

For sheep, a mean peak plasma concentration (Cmax) of 6.20 ng/ml was observed following a topical dose of 1 mg/kg. The half-life in plasma was 6.4 days with mean area under the curve (AUC last) value of 48.8 ng*day/ml.

For goats, peak mean plasma concentrations ranging from 3 to 13.1 ng/ml were observed on average from 17 hours to 2 days post dose. The mean half-life in plasma ranged from one day to up to 5 days with area under the curve mean values ranging from 15.7 to 39.1 ng*day/ml.

An in vitro microsomal metabolism study was conducted using liver microsomes isolated from cattle, sheep and goats. It showed that the differences in pharmacokinetics observed between cattle, sheep and goats do not result from differences in the rate or extent of metabolism but suggests more complete absorption of eprinomectin by cattle.

Environmental properties

Extremely dangerous to fish and aquatic life (see also section 5.5).
Like other macrocyclic lactones, eprinomectin has the potential to adversely affect non-target organisms.
Following treatment, excretion of potentially toxic levels of eprinomectin may take place over a period of several weeks. Faeces containing eprinomectin excreted onto pasture by treated animals may reduce the abundance of dung feeding organisms which may impact on the dung degradation.
Eprinomectin is very toxic to aquatic organisms, is persistent in soils and may accumulate in sediments.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 36 months.
Shelf life after first opening the immediate packaging: 6 months.

5.3 Special precautions for storage

For Squeeze pour containers (1 L): Keep the container in the outer container in order to protect from light.

For Flexi-pack containers (2.5 L, 3 L and 5 L): Protect from light.

5.4 Nature and composition of immediate packaging

High density polyethylene container with a polypropylene tamper evident screw cap which consists of the following:
1L 'Squeeze pour' packs.
2.5 L, 3 L and 5 L 'Flexi' packs.
Pack sizes 1 L, 2.5 L, 3 L and 5 L.
Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.
The veterinary medicinal product should not enter watercourses as eprinomectin may be dangerous for fish and other aquatic organisms. Do not contaminate lakes or waterways with the veterinary medicinal product or used containers.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd.

7. MARKETING AUTHORISATION NUMBER(S)

VPA10987/109/001

8. DATE OF FIRST AUTHORISATION

22/05/2015

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

03/03/2026

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).